1-3 of 3
Debra Rembert, RN, MSN, NP
Close
Sort by
Journal Articles

Impact Of Route Of Bortezomib (B) Administration On Dose Intensity and Time To Dose Reduction In Previously Untreated Patients (Pts) With Multiple Myeloma (MM)

Robert M Rifkin, MD, FACP, Clara Chen, MS, Rahul Dhanda, Ph.D, Debra Rembert, RN, MSN, NP, Abbie Ba-Mancini, BS MBA, Esprit Ma, MPH, Yanyan Zhu, Ph.D, MPH, Edward Dow, MD, Liviu Niculescu, MD
Journal: Blood
Blood (2013) 122 (21): 1941.
https://doi.org/10.1182/blood.V122.21.1941.1941
Published: 2013
Journal Articles

Association Between Treatment Adherence and Response Among Patients With Chronic Myeloid Leukemia (CML) Receiving First-Line TKIs In The Community Setting

Nicholas J. Di Bella, MD, Debajyoti Bhowmik, PhD, Menaka Bhor, PhD, Mark Yap, BSN, RN, Brooke Middlebrook, Debra Rembert, RN, MSN, NP, Rahul Dhanda, PhD, Zachary Cain, PharmD, Tony Okoro, PharmD, Bjorn Bolinder, MBA, Elias J. Jabbour, MD
Journal: Blood
Blood (2013) 122 (21): 2733.
https://doi.org/10.1182/blood.V122.21.2733.2733
Published: 2013
Journal Articles

Comparable Outcomes With Bortezomib-Cyclophosphamide-Dexamethasone (VCD) and Bortezomib-Lenalidomide-Dexamethasone (VRD) For Initial Treatment Of Newly Diagnosed Multiple Myeloma (MM)

Shaji K Kumar, MD, Ann E Engebretson, Francis K Buadi, MD, Martha Q Lacy, MD, Angela Dispenzieri, MD, Mei Sheng Duh, MPH, Sc.D, Marie-Hélène Lafeuille, MA, Patrick Lefebvre, MA, B.Sc, Wendy Y Cheng, MPH, MPhil, Katherine Dea, MA, Mark Yap, BSN, RN, Shanmugapriya Saravanan, MS, Iwen Pan, Ph.D, Debra Rembert, RN, MSN, NP, Rahul Dhanda, PhD, Liviu Niculescu, MD, Abbie Ba-Mancini, BS MBA, Esprit Ma, MPH, Maureen Quick, RN, MS, OCN, S. Vincent Rajkumar, MD
Journal: Blood
Blood (2013) 122 (21): 3178.
https://doi.org/10.1182/blood.V122.21.3178.3178
Published: 2013